REAL STORIES. REAL WORKERS. REAL STRENGTH.
Latest Stories
BeOne Medicines is planning to invest $300 million in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey. This investment highlights a commitment to American industry and production, potentially benefiting workers and supporting the local economy.
Eli Lilly intends to file for regulatory approval of its investigational anti-obesity drug Retatrutide in early 2027 after successful late-stage trial results, targeting obesity and related conditions.
Bristol Myers joins other pharmaceutical companies in leveraging AI technology by teaming up with Nvidia to build a new AI data center. Meanwhile, in the industry, Novartis gains an advantage in the competitive market with a kidney drug. These developments showcase the ongoing innovation and competition within the pharmaceutical sector, impacting American industry and production.
The FDA has granted approval for MSD’s Keytruda and Keytruda Qlex, in combination with Padcev, for the treatment of adults with MIBC. This development could have implications for the pharmaceutical industry and potentially benefit patients in need of advanced treatment options.
Seven pharma companies, including industry leaders Lilly and Regeneron, have been selected for the FDA PreCheck pilot program aimed at enhancing the resilience of the US drug supply chain. This initiative is a positive step towards ensuring the efficiency and reliability of pharmaceutical production in America, benefiting workers, companies, and the overall industry.
Seven pharma companies, including industry leaders Lilly and Regeneron, have been selected for the FDA PreCheck pilot program aimed at strengthening the US drug supply chain. This initiative could have positive implications for American industry, workers, production, and supply chains in the pharmaceutical sector.
In an interview with Endpoints News, John Reed, Johnson & Johnson’s R&D chief, shared insights on the company’s approach to drug development, acquisitions, and focus areas like obesity and cardiovascular disease. This discussion provides valuable information for those interested in the pharmaceutical industry and potential advancements that could impact American healthcare and innovation.
The FDA has recently cleared multiple oncology products, including therapies, diagnostic tools, and imaging agents. This approval brings new options for cancer treatment and diagnosis, potentially impacting American healthcare and pharmaceutical industries.
Regenxbio is set to resubmit its gene therapy for Hunter syndrome following the FDA’s backtrack on a previous rejection, signaling a step towards clearing the backlog of Makary-era rejections. This development provides valuable industry insight into the agency’s alignment with drugmakers and could impact American competitiveness in the pharma sector.
AdvanCell has opened its U.S. global headquarters and a 128,000-square-foot manufacturing facility in Greater Boston, marking a significant expansion. This move integrates corporate operations with manufacturing capabilities and supports growth in the radiopharmaceutical sector, with positive implications for jobs and the regional economy.
News on U.S. pharmaceutical manufacturing, biotech, drug production, medical supply chains, facilities, investment, and the workers supporting American health innovation.
Top Stories
